Mode
Text Size
Log in / Sign up

Prospective observational study identifies 2,504 potential drug-drug interactions among hospitalized patients with acute coronary syndromeHeart Patients Face Hidden Risks From Common Drug Mixes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize high potential drug-drug interaction rates in ACS patients; involve clinical pharmacists in management.

This prospective observational cohort study included 371 hospitalized patients with acute coronary syndrome at Assiut University Heart Hospital, a tertiary care hospital in Upper Egypt. The exposure involved the prescription of multiple drugs, including aspirin, ticagrelor, and ramipril. Follow-up duration was not reported.

The analysis detected a total of 2,504 potential drug-drug interactions (pDDIs). The mean number of drugs prescribed per patient was 7.78 ± 1.73. Severity class distribution included Class C at 74.76%, Class D at 10.02%, and Class X at 0.04%. There was no comparator group.

Within category D, aspirin and ticagrelor represented the most prevalent pDDIs, accounting for 92.4% of 232 cases. The most frequent interacting pair in class C involved ramipril and aspirin, comprising 17.2% of 281 instances. Factors significantly associated with specific pDDIs included STEMI patients, length of hospital stay, and a higher number of prescribed drugs.

Overall safety outcomes including adverse events, serious adverse events, discontinuations, and tolerability were not reported. As an observational design, associations identified via logistic regression do not imply causation. Study also assesses potential interactions, not confirmed clinical adverse events. Current practice relevance suggests clinical pharmacists ought to be more actively involved in managing complex drug regimens and improving future therapeutic outcomes.

Imagine you are in the hospital after a heart attack. Your doctor prescribes several medications to help you recover. You trust that these pills are working together to save your life. But what if some of them are secretly working against each other?

A new study from Egypt reveals a hidden danger for heart patients. It found that common drug combinations can cause serious problems. This is a risk many patients and even some doctors may not fully see.

An acute coronary syndrome (ACS) is a serious heart condition. It includes heart attacks and unstable angina (chest pain). This condition is a leading cause of death worldwide.

To treat ACS, doctors often prescribe a "cocktail" of drugs. Patients might take blood thinners, blood pressure pills, and cholesterol reducers all at once. The goal is to prevent another heart attack.

But taking many medicines increases the chance of a bad reaction. This is called a potential drug-drug interaction (pDDI). It happens when two drugs affect each other. One drug might make the other too strong or too weak. This can lead to side effects or treatment failure.

Currently, there is not enough help for doctors managing these complex drug lists. This study highlights why that needs to change.

In the past, doctors focused on treating the heart condition itself. They might check for major drug conflicts, but subtle ones were often missed. The old way assumed that if a drug worked well alone, it would work well with others.

But here’s the twist: The sheer number of pills changes the game. When a patient takes seven or eight medications, the risk of a hidden conflict skyrockets.

This study shows that simply counting the number of drugs a patient takes can predict their risk. It’s not just about the specific heart condition. It’s about the total burden of medication on the body.

Think of your body like a busy highway system. Each drug is a car trying to get to a specific exit (its target). A drug interaction is like a traffic jam or a roadblock.

For example, some drugs are processed by the same liver enzyme. That enzyme is like a single toll booth on the highway. If two drugs arrive at the same time, they have to wait. This makes them stay in your blood longer than intended. The drug becomes too strong, like a traffic jam causing a backup.

Other drugs might block each other’s paths entirely. One drug might close the exit ramp another drug needs. This makes the second drug useless.

In this study, researchers used a computer tool called Lexi-Interact. This tool acts like a GPS for drug safety. It scans a patient’s list of medications and flags potential traffic jams before they happen.

Researchers looked at 371 patients admitted to a heart hospital in Upper Egypt. All patients had an acute coronary syndrome. The team tracked every drug prescribed to these patients. They used the Lexi-Interact tool to check for potential interactions.

The study lasted for a specific observation period. The goal was to see how often these hidden conflicts occurred.

The results were eye-opening. Out of 371 patients, a total of 2,504 potential drug interactions were detected. That is an average of nearly seven interactions per patient.

The researchers categorized these interactions by severity.

  • Category C is moderate. It requires monitoring but is usually manageable.
  • Category D is serious. It requires therapy modification.
  • Category X is dangerous. The drugs should not be used together.

Most interactions (74.76%) were Category C. However, over 10% were Category D, which is a serious concern.

The most common serious conflict involved aspirin and ticagrelor. These are both blood thinners. Taking them together is sometimes necessary, but it significantly raises the risk of bleeding.

Another frequent conflict was between ramipril (a blood pressure drug) and aspirin. This pair was the most common moderate interaction.

The study also found clear patterns in who was at highest risk:

  • Patients with STEMI (a severe type of heart attack).
  • Patients who stayed in the hospital longer.
  • Patients prescribed a higher number of drugs.

But there’s a catch.

This study highlights a critical gap in patient care. While these interactions are "potential," they are very real in practice. Clinical pharmacists are uniquely trained to spot these issues. They can review a patient's full medication list and suggest changes.

The researchers suggest that pharmacists should be more involved in heart teams. By checking drug lists daily, they can prevent these traffic jams before they harm the patient. This collaboration could improve safety and lower healthcare costs.

If you or a loved one has a heart condition, this study is a reminder to be proactive.

You should always keep a current list of every medication you take. This includes over-the-counter drugs and supplements. Bring this list to every doctor’s appointment.

Ask your doctor or pharmacist: "Do all my medications work well together?" If you are in the hospital, ask if a pharmacist can review your chart.

This study was conducted at a single hospital in Upper Egypt. The results might not be exactly the same in other countries or hospitals. The study also focused only on potential interactions detected by software. It did not track if every interaction actually caused a physical harm to the patient. More research is needed to confirm these findings in different settings.

The next step is to integrate pharmacists into routine heart care. Hospitals need systems that automatically flag high-risk drug combinations for review. Future research will look at whether adding pharmacist reviews actually reduces hospital stays and improves survival rates. For now, this study puts a spotlight on a hidden danger that needs more attention.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundPotential drug-drug Interactions (pDDIs) are a serious concern in cardiovascular patients and are responsible for most adverse drug reactions and drug-related hospital admissions. Clinically significant pDDIs may injure patients, create adverse outcomes, and impact healthcare costs. Therefore, pDDIs control is critical for the improvement of prescription drug safety.AimThe present study aimed to assess potential pDDIs among cardiovascular patients at a Tertiary Care Hospital in Upper Egypt.MethodsA prospective observational study was performed on acute coronary syndrome (ACS) patients attending Assiut University Heart Hospital. The Lexi-Interact online was used to assess pDDIs. Multiple logistic regression was used to identify the factors associated with pDDIs.ResultsA total of 371 patients attending Assiut University Heart Hospital were recruited for the study. A total of 2,504 pDDIs were detected among the patients. The mean number of drugs prescribed per patient was 7.78 ± 1.73. Class C, D, and X DDIs were found in 74.76%, 10.02%, and 0.04%, respectively. Aspirin and ticagrelor were the most prevalent pDDIs under category D (232, 92.4%). A combination of ramipril and aspirin was the most frequently encountered interacting pair in the class C (281, 17.2%). STEMI patients, length of hospital stay, and a higher number of prescribed drugs were significantly associated with the occurrence of pDDIs, according to multiple logistic regression.ConclusionPatients with ACS were frequently exposed to pDDIs with the highest drug-related problems, treatment failure, and negative consequences. Therefore, clinical pharmacists ought to be more involved in managing complex drug regimens and improving therapeutic outcomes.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.